CAMBRIDGE, Mass., Dec. 3 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. today announced that its investor event at the annual American Society of Hematology (ASH) meeting will be webcast live and may be accessed by visiting the Investors section of the Company’s website, www.millennium.com.
(Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )
The presentation will be delivered by Millennium senior management as well as clinical investigators and will include an overview of clinical trial data for VELCADE(R) (bortezomib) for Injection. The presentation will be delivered at 7:15 p.m. ET on Monday, December 10, 2007 from the Twelve Hotel in Atlanta, Georgia. The presentation will be archived for 30 days.
About Millennium
Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE, a novel cancer product, and has a robust clinical development pipeline of product candidates. The Company’s research, development and commercialization activities are focused in two therapeutic areas: oncology and inflammation. By applying its knowledge of the human genome, understanding of disease mechanisms and industrialized drug discovery platform, Millennium is developing an exciting pipeline of innovative product candidates. The Company’s website is www.millennium.com.
Editors’ Note: This press release is also available under the Media section of the Company’s website at: www.millennium.com.
CONTACT: Kyle Kuvalanka of Millennium Pharmaceuticals, Inc.,
+1-617-761-4734
Web site: http://www.millennium.com//
Company News On-Call: http://www.prnewswire.com/comp/114562.html /
